Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $32.25.

DTIL has been the topic of several research reports. JonesTrading reissued a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a research note on Friday, April 17th. Jefferies Financial Group reiterated a “buy” rating and set a $19.00 target price on shares of Precision BioSciences in a report on Friday, March 13th. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Wall Street Zen raised Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Oppenheimer initiated coverage on Precision BioSciences in a research note on Tuesday. They set an “outperform” rating and a $20.00 price objective for the company.

Precision BioSciences Trading Up 4.2%

DTIL opened at $6.77 on Tuesday. The company has a quick ratio of 14.02, a current ratio of 14.02 and a debt-to-equity ratio of 0.29. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $8.82. The stock has a market cap of $174.67 million, a PE ratio of -1.84 and a beta of 1.30. The business has a 50 day moving average of $6.99 and a 200-day moving average of $5.45.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The firm had revenue of $10.84 million during the quarter, compared to analysts’ expectations of $4.05 million. Equities research analysts predict that Precision BioSciences will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Precision BioSciences

Several large investors have recently modified their holdings of the stock. HBK Sorce Advisory LLC purchased a new stake in Precision BioSciences during the 4th quarter valued at about $38,000. Engineers Gate Manager LP purchased a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $43,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $52,000. Miller Financial Services LLC increased its position in shares of Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences in the 3rd quarter worth approximately $72,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.